Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.76 Insider Own17.08% Shs Outstand58.88M Perf Week-11.66%
Market Cap84.79M Forward P/E- EPS next Y-0.92 Insider Trans0.00% Shs Float48.83M Perf Month3.60%
Income-44.65M PEG- EPS next Q-0.21 Inst Own23.53% Short Float0.27% Perf Quarter-4.00%
Sales0.11M P/S770.79 EPS this Y5.68% Inst Trans-18.47% Short Ratio0.58 Perf Half Y0.70%
Book/sh1.74 P/B0.83 EPS next Y-15.88% ROA-42.63% Short Interest0.13M Perf Year-65.80%
Cash/sh1.54 P/C0.94 EPS next 5Y- ROE-47.57% 52W Range1.14 - 4.70 Perf YTD-11.66%
Dividend Est.- P/FCF- EPS past 5Y9.74% ROI-43.29% 52W High-69.36% Beta1.21
Dividend TTM- Quick Ratio7.94 Sales past 5Y0.00% Gross Margin-1014.62% 52W Low26.32% ATR (14)0.14
Dividend Ex-Date- Current Ratio8.90 EPS Y/Y TTM-23.11% Oper. Margin-52654.01% RSI (14)50.66 Volatility9.42% 10.11%
Employees66 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin-41448.03% Recom1.40 Target Price8.09
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q32.98% Payout- Rel Volume0.93 Prev Close1.48
Sales Surprise-97.19% EPS Surprise24.35% Sales Q/Q- EarningsMay 08 BMO Avg Volume226.01K Price1.44
SMA203.95% SMA50-0.48% SMA200-27.47% Trades Volume209,724 Change-2.70%
Date Action Analyst Rating Change Price Target Change
Apr-05-23Upgrade Guggenheim Neutral → Buy $8
Feb-28-22Downgrade Guggenheim Buy → Neutral
Oct-28-21Upgrade Raymond James Outperform → Strong Buy $10 → $14
Mar-11-21Upgrade Guggenheim Neutral → Buy $16
Nov-06-20Upgrade SVB Leerink Mkt Perform → Outperform $7 → $10
Oct-08-20Initiated H.C. Wainwright Buy $11
Jun-17-20Initiated BTIG Research Buy $12
Apr-30-20Upgrade Raymond James Mkt Perform → Outperform
Jun-05-19Downgrade SunTrust Buy → Hold $55 → $5
Jun-05-19Downgrade Robert W. Baird Outperform → Neutral $58 → $6
May-21-24 02:30PM
May-08-24 11:57AM
Apr-30-24 07:30AM
Apr-24-24 07:30AM
11:53AM Loading…
Mar-21-24 11:53AM
Mar-19-24 07:30AM
Feb-22-24 07:30AM
Jan-25-24 07:30AM
Jan-04-24 07:00AM
Dec-01-23 09:55AM
Nov-28-23 09:35AM
Nov-06-23 09:35AM
07:30AM Loading…
Nov-01-23 07:30AM
Oct-31-23 07:12PM
Sep-11-23 07:00AM
Sep-01-23 02:38PM
Aug-31-23 10:15AM
Aug-30-23 07:30AM
Aug-10-23 07:30AM
Jun-28-23 07:30AM
Jun-21-23 07:00AM
May-11-23 07:30AM
May-03-23 07:14AM
Apr-18-23 04:01PM
Apr-14-23 04:01PM
Apr-13-23 11:22AM
09:08PM Loading…
Apr-11-23 09:08PM
Apr-07-23 10:21AM
Apr-05-23 11:57AM
Apr-04-23 04:14PM
Mar-23-23 08:21AM
Mar-22-23 07:30AM
Jan-05-23 07:30AM
Dec-21-22 07:30AM
Nov-09-22 07:40AM
Sep-29-22 07:30AM
Sep-09-22 07:30AM
Sep-08-22 07:30AM
Sep-07-22 10:54AM
Aug-17-22 12:00PM
Aug-11-22 12:00PM
Aug-05-22 07:00AM
Jul-26-22 03:36PM
Jul-06-22 07:30AM
Jun-29-22 12:02PM
May-17-22 07:30AM
May-13-22 01:55PM
May-12-22 07:30AM
Mar-31-22 02:56PM
Mar-24-22 08:55AM
Mar-17-22 10:03AM
Mar-08-22 07:30AM
Feb-28-22 12:10PM
Feb-16-22 07:30AM
Feb-08-22 07:30AM
Jan-10-22 07:30AM
Jan-05-22 08:00AM
Nov-15-21 03:39PM
Nov-11-21 07:30AM
Nov-08-21 06:17AM
Nov-05-21 07:30AM
Nov-03-21 07:30AM
Oct-28-21 09:51AM
Oct-27-21 07:30AM
Oct-19-21 10:08AM
Oct-12-21 07:30AM
Sep-09-21 07:30AM
Sep-08-21 07:30AM
Aug-10-21 09:17AM
Aug-06-21 07:30AM
Aug-05-21 07:30AM
Jul-28-21 03:45PM
Jun-17-21 07:30AM
Jun-08-21 07:30AM
May-30-21 05:22AM
May-21-21 07:30AM
May-12-21 07:30AM
May-11-21 04:30PM
Apr-15-21 07:30AM
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.